The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.

开始日期2023-01-09

申办/合作机构

Oregon Health & Science University

100 项与醋酸乌利司他相关的临床结果

登录后查看更多信息

100 项与醋酸乌利司他相关的转化医学

登录后查看更多信息

100 项与醋酸乌利司他相关的专利（医药）

登录后查看更多信息

993

项与醋酸乌利司他相关的文献（医药）

2025-06-01·CONTRACEPTION

Uses of ulipristal acetate beyond emergency contraception: A narrative review

Review

作者: Ebersole, Ashley M ; Edelman, Alison ; Cleland, Kelly ; Liberty, Abigail ; Lyman, Elizabeth

OBJECTIVES:

Ulipristal acetate (UPA) is a selective progesterone receptor modulator and the most effective oral emergency contraceptive (EC) method available in the United States. The aim of this review is to identify and describe uses of UPA beyond EC and to further discuss the concerns regarding the possible off-target liver effects.

STUDY DESIGN:

We conducted a literature search in August 2024, using Embase, Medline (PubMed), and Cochrane, utilizing a combination of MeSH and keywords for UPA, excluding animal studies, and limiting to English language publications. After excluding duplicates using covidence, two authors reviewed the remaining 610 results and identified 340 studies. We further excluded case reports and case series.

RESULTS:

UPA has shown significant promise for indications outside of EC, most notably treatment of uterine leiomyomas, but also ongoing contraception, prevention and treatment of breast cancer, and abnormal uterine bleeding. While UPA has extensive potential for use both within and beyond reproductive health, unfortunately any ongoing development is at a standstill due to concerns regarding its possible role in causing serious liver injury. The role of UPA in causing drug-induced liver injury is not confirmed and preclinical studies during development did not demonstrate a concern that UPA causes drug-induced liver injury.

CONCLUSIONS:

Access to UPA is crucial not only for EC but for the treatment of many other gynecological and nongynecological conditions.

IMPLICATIONS:

Ulipristal acetate (UPA) has shown significant promise for indications outside of EC, including uterine leiomyomas, prevention and treatment of breast cancer, and abnormal uterine bleeding. Access to UPA is crucial not only for EC but for the treatment of many other gynecologic and non-gynecologic conditions.

2025-05-04·JOURNAL OF CLINICAL CHILD AND ADOLESCENT PSYCHOLOGY

Adolescent Client and Clinician Predictors of Measurement-Based Care Fidelity in Community Mental Health Settings

Article

作者: Lane, Elizabeth ; Ehrenreich-May, Jill ; Ginsburg, Golda S. ; Jensen-Doss, Amanda ; Woodard, Grace S.

OBJECTIVE:

Regularly administering outcome measures, measurement-based care (MBC), informs clinical decision-making and improves youth mental health. Understanding predictors of high-fidelity MBC delivery helps ensure all youth can benefit from this evidence-based practice. Research on client and clinician predictors of MBC fidelity has mixed findings.

METHOD:

Participants included 53 clinicians and 115 adolescents from a randomized controlled effectiveness trial with MBC only and MBC + Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UPA) conditions. Clients and clinicians reported demographic information. Clinicians completed broad- and narrow-band attitude measures. MBC fidelity was operationalized using the implementation index, combining rates of administering and viewing questionnaires, using objective MBC data.

RESULTS AND DISCUSSION:

The average MBC fidelity was 56.75% (SD = 30.36) and was significantly higher in the MBC only condition (M = 67.46%, SD = 27.63%) than in MBC + UPA condition (M = 46.58%, SD = 29.52%; p = .012). Clients identifying as White received significantly higher MBC fidelity than youth not identifying as White. Youth ethnicity, family income, age, severity, and number of sessions did not significantly predict MBC fidelity. Clinicians with less experience at their agency, less confidence, and who found manualized treatments less appealing, had significantly higher MBC fidelity than other clinicians. These results can inform future efforts to increase fidelity and equity in MBC delivery.

2025-04-01·Rheumatology and Therapy

Effective Second-Line b/tsDMARDs for Patients with Rheumatoid Arthritis Unresponsive to First-Line b/tsDMARDs from the FIRST Registry

Article

作者: Tanaka, Hiroaki ; Todoroki, Yasuyuki ; Nagayasu, Atsushi ; Fukuyo, Shunsuke ; Kubo, Satoshi ; Nakayamada, Shingo ; Sakai, Hidenori ; Fujita, Yuya ; Kusaka, Katsuhide ; Tanaka, Yoshiya ; Matsunaga, Satsuki ; Satoh-Kanda, Yurie ; Miyagawa, Ippei ; Ohkubo, Naoaki ; Aritomi, Takafumi ; Nohara, Hirotsugu ; Miyazaki, Yusuke ; Kanda, Ryuichiro ; Yamaguchi, Ayako ; Ueno, Masanobu

INTRODUCTION:

For patients with rheumatoid arthritis (RA) unresponsive to first-line biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), the selection of second-line b/tsDMARDs is crucial to prevent progression to difficult-to-treat rheumatoid arthritis (D2TRA). However, indicators for selection are lacking. This study aimed to identify optimal second-line b/tsDMARDs among the phase III treatment strategies based on European League Against Rheumatism (EULAR) RA management recommendations.

METHODS:

A total of 687 RA patients treated with second-line b/tsDMARDs (tumor necrosis factor inhibitor (n = 246), interleukin-6 receptor inhibitor [n = 195], cytotoxic T-lymphocyte-associated protein 4 immunoglobulin [n = 119], and Janus kinase inhibitor [n = 127]) were enrolled between October 2013 and April 2023. Rates of patients achieving Clinical Disease Activity Index (CDAI) remission and CDAI low disease activity (LDA), changes in CDAI, persistence rates, and adverse events within 24 weeks after treatment initiation were compared among the four groups. Propensity score-based inverse probability of treatment weighting (PS-IPTW) was used to minimize selection bias.

RESULTS:

After PS-IPTW adjustment, the Janus kinase inhibitor (JAKi) group had the highest persistence rate among the four groups. At 24 weeks, the JAKi group showed the greatest improvement in CDAI and the highest CDAI remission rate. Among patients treated with JAKi as second-line b/tsDMARDs, upadacitinib (UPA) was most likely to achieve CDAI remission at 24 weeks. The comparison between the UPA group (n = 32) and the non-UPA JAKi group (tofacitinib and baricitinib [n = 95]) showed comparable persistence rates but significantly lower CDAI scores and higher CDAI remission rate at 24 weeks in the UPA group. No significant difference was noted in the overall incidence of adverse events among the four groups treated with b/tsDMARDs or between the groups treated with JAKi.

CONCLUSIONS:

Selecting JAKi, especially UPA, may effectively improve the disease activity for RA patients unresponsive to first-line b/tsDMARDs. Further large-scale studies are needed to clarify the efficacy and safety of UPA.

TRIAL REGISTRATION:

FIRST registry (approval number#04-23): October 2013, retrospectively registered.

项与醋酸乌利司他相关的新闻（医药）

2025-03-29

·药事纵横

7500万美元！一家biotech在印度建立CGT工厂

声明：因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及）;本文不构成任何投资建议。近日，印度药企Bharat Biotech 宣布：已在印度建立其首个细胞和基因治疗 (CGT) 工厂，并投资7500万美元。据悉，该公司正在研究两款细胞疗法和3款基因疗法，预计其新疗法将在未来3年内上市。该公司正将把重点从核心疫苗业务扩展到复杂的细胞和基因治疗，据市场研究公司 Precedence Research 的数据，该市场预计从 2024 年的 212.8亿美元增长五倍以上至 2034 年的 1174.6 亿美元。该 50,000 平方英尺的设施专门用于生产高滴度病毒载体，包括 AAV（腺相关病毒）、慢病毒和腺病毒，以支持基因治疗应用。该设施拥有最先进的能力，可在其平台上生产不同的产品，并为血癌、实体器官癌和遗传性疾病提供治疗选择。Bharat Biotech 首席开发官 Raches Ella 表示，其目标是使基因疗法普及化，就像疫苗一样，让所有人都能负担得起这些疗法。细胞疗法和基因疗法比传统疗法更贵，动辄几百万美元。Bharat Biotech 执行主席 Krishna Ella 博士表示：“与全球相比，印度仍处于CGT发展初级阶段，如果在印度市场售卖这些CGT疗法，售价约500万卢比（约57900美元），或许定价比这还低。”作为一家在开发抗病毒疫苗方面拥有数十年经验的公司，Bharat Biotech 具有独特的资质，可以进行大规模生产，从而加快临床产品的商业化。该公司还与威斯康星大学麦迪逊分校的 Krishanu Saha 教授合作开发下一代 CAR-T疗法。Bharat Biotech 是一家印度生物技术公司，在疫苗和生物治疗领域有突出表现，成立于1996 年，截至 2023 年有 1526 名员工，公司致力于开发价格亲民、安全且高质量的疫苗和生物治疗产品。其拥有 145 项全球专利，在生物信息学、分子流行病学、分子生物学、微生物学、细菌学、病毒学、免疫学、生物化学、临床研究、工业生物技术、制剂和产品开发等领域开展前沿研究。Bharat Biotech已开发出多种突破性的疫苗和生物治疗产品，包括世界上第一种伤寒结合疫苗 Typbar TCV、用于治疗糖尿病足溃疡的生长因子凝胶 Regen - D®，以及使 Revac - B mcf® 得以生产的专利技术 Himax®。Revac - B mcf® 是第一种重组乙型肝炎疫苗，与同类疫苗相比，具有最高水平的抗原回收率。其新冠疫苗 Covaxin4是印度本土开发的全病毒灭活新冠疫苗，与印度医学研究理事会（ICMR）和印度国家病毒研究所（NIV）合作研发。2021 年 1 月 3 日获得印度药品管理总局批准紧急使用。研究显示，Covaxin 对儿童具有良好的安全性和免疫原性。其结核病疫苗 MTBVAC与 Biofabri 密切合作进行临床试验。MTBVAC 是第一个从人类身上分离出来的结核分枝杆菌的减毒活疫苗，2024 年已开始在印度成年人中进行安全性和免疫原性试验，计划于 2025 年开始关键的安全性、免疫原性和有效性试验。它还与葛兰素史克公司建立产品转让合作伙伴关系，负责生产葛兰素史克公司开发的疟疾疫苗 RTS，S/AS01E 的 S 抗原成分。根据协议，巴拉特生物技术公司预计在 2029 年成为该疫苗的唯一供应商。研发管线参考资料：https://www.fiercepharma.com/manufacturing/bharat-biotech-enters-cell-and-gene-therapy-market-75m-production-investment

细胞疗法疫苗免疫疗法基因疗法上市批准

2025-02-14

·生物制品圈

mRNA序列设计|编码区序列（CDS）设计与优化全解析

导读：mRNA序列设计是mRNA疫苗/药物开发的第一难关，序列骨架直接影响mRNA的稳定性、翻译效率和免疫原性等，是mRNA成功开发的关键决策之一。mRNA由编码区域（CDS）和非编码区域（5' cap、5' UTR、3' UTR和3' poly A尾）构成。其中编码区决定了经mRNA递送的功能性蛋白的成药潜力。本期文章菌菌将聚焦于CDS编码序列，结合mRNA巨头公司Moderna、BioNTech/辉瑞、Arcturus等实际应用案例解析其设计与优化策略。 01 mRNA序列全解析 5’ Cap的作用是保护mRNA不被外切酶降解、维持其结构稳定性，并与3’端的poly A尾、poly A结合蛋白（PAPB）和翻译起始因子蛋白协同作用，起始蛋白质的翻译。出于真核生物体内表达的考虑，mRNA常用的帽结构为Cap1。IVT mRNA常用的加帽方式包括酶法加帽和共转录加帽。 5’ UTR和3’ UTR的功能为调控mRNA的翻译，影响mRNA的稳定性。在mRNA疫苗/药物的研发过程，UTR的设计原则为：直接选取人高表达基因的mRNA、使用病毒来源UTR、或基于算法全新设计UTR序列。如前所述，poly A尾与Cap结构、poly A尾结合蛋白（PAPB）协同起始mRNA的翻译程序。已被证明有效的polyA序列包括长度在100~120 nt的纯A序列、或分段式polyA序列（例如辉瑞/BioNTech的30A + 10(GCAUAUGACU) + 70A）。除以上非编码的元件外，编码区域（CDS）的可翻译率无疑是至关重要的。CDS的设计和优化策略为：首先确定目标蛋白的氨基酸序列（天然蛋白序列或具有增强功能的突变体），其次是针对目标物种进行密码子优化。下文中菌菌将结合典型案例分析mRNA CDS的设计与优化，主要包括两个步骤：首先是设计目标蛋白氨基酸序列，再基于密码子设计并优化mRNA CDS序列。图示 mRNA序列设计原则 02 编码蛋白的氨基酸序列设计与优化 mRNA CDS序列的设计基础是确定目标蛋白的氨基酸序列。氨基酸排列顺序是蛋白质一级结构和高级结构的基础，直接决定蛋白质的生物学功能。天然活性蛋白的氨基酸序列是CDS序列设计的可选方案之一。然而，随着蛋白质工程的成熟发展，筛选或定向改造具有增强功能的突变体能够进一步改善蛋白或多肽分子的成药特性。这一工程化设计思维也逐渐应用于mRNA CDS序列的设计，相关典型案例如下：案例1：报告基因eGFP 绿色荧光蛋白（GFP, green fluorescent protein）来源于水母Aequorea victoria，能够在原核和真核生物体内表达荧光蛋白。2008年，发现和发展GFP蛋白的三位科学家Osamu Shimomura、Martin Chalfie 和Roger Tsien（钱永健）被授予了诺贝尔化学奖。然而GFP发光信号较弱，科学家发现了一种GFP突变体，得到了增强型绿色荧光蛋白（eGFP, enhanced green fluorescent protein）。相比天然版本的GFP，eGFP的荧光强度提高了35倍。目前，eGFP mRNA已成为mRNA研究领域必不可缺的工具，用于细胞转染对照、mRNA序列优化、目标蛋白示踪以及递送系统开发。图示耀海RNASci平台eGFP mRNA的细胞转染评估报告基因mRNA的使用对于LNP递送系统的开发至关重要，例如：绿色荧光蛋白mRNA、红色荧光蛋白mCherry mRNA、荧光素酶mRNA（Luciferase mRNA）等。耀海生物RNASci平台提供多种报告基因mRNA（转染级和高纯度级），在体内外均具备高表达水平，高质量满足mRNA的细胞转染和动物试验需求。欢迎垂询：13380332910。案例2：Moderna mRNA-3705（hMMUT多态性）基因/蛋白的多态性也是目标蛋白氨基酸序列选择的考量之一。 mRNA-3704和mRNA-3705是Moderna开发的针对甲基丙二酸血症/酸尿症（MMA）的管线，MMA最常见的致病因素是甲基丙二酰辅酶A变位酶（MMUT）缺陷或缺失。 mRNA-3704和mRNA-3705均编码人MMUT，二者的区别在于，mRNA-3704的第671位氨基酸是缬氨酸（V671），而mRNA-3705的671位氨基酸替换为异亮氨酸（I671）。mRNA-3705的编码序列的来源为健康人群MMUT在671位点的多态性。图示 Moderna mRNA-3704/3705的序列示意图案例3：Arcturus ARCT-810（OTC突变体）参考蛋白/多肽药物的开发，设计一种蛋白突变体以改善其半衰期等性能，也是mRNA上游设计中的重要步骤。 ARCT-810是Arcturus的在研管线，靶点为鸟氨酸氨甲酰转移酶（OTC），针对鸟胺酸氨甲酰基转移酶缺乏症（OTCD）。ARCT-810通过专有脂质纳米颗粒（LNP）将mRNA递送到细胞中，mRNA被翻译成功能性的OTC，使患者自身肝细胞产生具有生物学功能的OCT酶。相比野生型OCT酶，ARCT-810存在3个氨基酸位点的改变，从而提高了OTC的半衰期，且增加了与线粒体的结合。图示 Arcturus ARCT-810序列示意图案例4：ReCode RCT2100（CFTR突变体）囊性纤维化（CF）是由囊性纤维化跨膜传导调节器（CFTR）基因突变引起的疾病，会导致患者进行性气道损伤和呼吸衰竭。ReCode正在开发一款基于mRNA蛋白替代疗法的管线——RCT2100。RCT2100编码CFTR mRNA，利用选择性器官靶向（SORT）LNP通过雾化器吸入给药，将mRNA特异性递送至与疾病有关的器官、组织和细胞。 RCT2100的mRNA编码区经过了优化。野生型CFTR蛋白存在一个特定的水解热点，而ReCode优化后的CFTR mRNA相比野生型的水解热点明显减少，有效维持mRNA的稳定性和翻译效率。图示 ReCode RCT2100序列示意图 03 mRNA CDS序列的设计与优化基于以上策略确定了目标蛋白的氨基酸序列，下一步是针对氨基酸序列设计优化mRNA序列，常用的策略为密码子优化。据报道，两种密码子优化策略（复合密码子家族优化和家族内密码子优化）已成功用于商业化mRNA疫苗CDS区的优化，包括Moderna新冠疫苗mRNA-1273和BioNTech/辉瑞疫苗BNT-162b2。当前主要以CAI（密码子适应指数）作为密码子优化的参数。经密码子优化后，mRNA-1273的CAI约为0.98，BNT-162b2的CAI约为0.95，二者均相比天然新冠病毒S蛋白编码基因（CAI＜0.7）大幅提高。 3.1 复合密码子家族优化对于精氨酸（Arg）编码基因来说，人体内使用CGN的频率高于AGR。然而，在病毒基因组内却恰恰相反。例如，新冠病毒的刺突蛋白包含42个Arg残基，其中30个由 AGR 密码子编码，仅12个由 CGN 密码子编码。在mRNA疫苗的CDS序列优化方面，辉瑞/BioNTech采用了典型的复合密码子优化策略，在BNT162b2的CDS区域减少了8个AGR密码子，对应增加了CGN密码子的频率。Moderna开发的mRNA-1273也使用了这一策略，将其中28个AGR密码子替换成了CGN。类似地，高表达的人核糖体蛋白中，81%的亮氨酸通过CUN密码子编码。因此，在mRNA疫苗BNT162b2和mRNA-1273中，多数的UUR被替换为CUN。 3.2 家族内密码子优化家族内密码子优化的原则是替换为高表达基因优选且被最丰富的tRNA解码的最佳同义密码子。在编码Arg的密码子中，CGG被认为是CGN家族中的最优解。基于这一原则，BNT162b2和mRNA-1273对Arg密码子进行了优化。同样地，在谷氨酸（Glu）密码子优化方面，mRNA-1273中的GAN家族密码子全部替换成了GAG。图示 2款商业化mRNA疫苗的密码子优化策略 04 结语众所周知，mRNA通过表达目标蛋白发挥预防或治疗效应，因此在mRNA CDS序列设计中，目标蛋白分子的设计是重中之重。编码蛋白的一级结构（氨基酸序列）直接影响功能性蛋白在体内的稳定性、半衰期和活性等成药关键特性。这一偏上游的分子设计在公共文章中反而鲜少提及，菌菌在本文通过典型案例进行了详细阐述。其次，密码子优化能够改善mRNA在目标宿主的翻译效率，对于mRNA-蛋白剂量水平也必不可少。密码子优化是基因合成、分子生物学领域的重要部分，可借助的工具包括多家生物技术公司推出的线上工具、以及百度推出的LinearDesign。参考文献 [1] Coughlan KA, Eybye M, Henderson N, DeAntonis CM, et al. Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy. Mol Genet Metab. 2024 Sep-Oct;143(1-2):108560. [2] Markey McNutt, MD, PhD, FACMG. It Translates: An Update on the ARCT-810 mRNA for OTC Deficiency. SIMD Annual Meeting 2024. [3] Daniella I，Dmitri B， Ella A M， et al. Functional Rescue of CFTR by Aerosolized Delivery of Optimized CFTR mRNA Using ReCode LNPs in Primary Human Bronchial Epithelial Cells Derived From Patients With Cystic Fibrosis. American Thoracic Society (ATS) 2022 International Conference.2022. [4] Xia X. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel). 2021 Jul 3;9(7):734. doi: 10.3390/vaccines9070734. 识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观，不代表本站立。

信使RNA疫苗

2025-01-24

·drugs

Abortion Pill Alternative Found in Morning-After Pill

FRIDAY, Jan. 24, 2025 -- When one abortion pill faces lawsuits, another may be waiting in the wings, a new study suggests. The study, published Jan. 23 in the journal NEJM Evidence , has found a potential alternative to the abortion pill mifepristone , offering yet another option at a time when access to reproductive health care faces increasing legal and political challenges. Researchers tested ulipristal acetate, the active ingredient in the emergency contraceptive pill Ella , as a substitute for mifepristone in the medication abortion regimen. The study found that when ulipristal acetate was used at double the typical dose of Ella followed by misoprostol, the regimen was 97% effective in terminating pregnancies up to nine weeks. No serious complications were reported among the 133 women who participated. All but four completed the termination of their pregnancies without further intervention, researchers reported. The findings dovetail with ongoing lawsuits targeting mifepristone, the only drug specifically approved for abortion in the United States. Typically, it works by blocking progesterone, a hormone necessary for pregnancy, and is followed by misoprostol, which causes contractions to end the pregnancy. Lead author Dr. Beverly Winikoff , president of the reproductive health research organization Gynuity Health Projects, told The New York Times that the U.S. Supreme Court’s 2022 decision to overturn Roe v. Wade increased her interest in exploring alternatives to mifepristone. “I was thinking, there’s maybe something else we can do,” Winikoff said. “Another option. And this one is already on the market.” It's important to note, however, that reproductive health experts warn that the study could fuel political controversy, because Ella is also marketed as a prescription morning-after pill to prevent pregnancy following unprotected sex. Abortion foes have long argued that morning-after pills like Ella can act as abortifacients, substances that cause abortion. These claims have been strongly debunked. Evidence shows that Ella, when taken at its standard 30-milligram dose, works by delaying ovulation, preventing fertilization. This study, which used a 60-milligram dose of ulipristal acetate combined with misoprostol, does not debunk the science of emergency contraception . But it may blur public perceptions of the line between contraception and abortion. “It’s going to put wind in the sails of abortion opponents who have been saying things like contraceptives can be abortifacients,” Mary Ziegler , a law professor and abortion expert at the University of California, Davis, told The Times. “This study being released will be difficult, I think, for abortion rights supporters to manage.” Kristi Hamrick , a spokeswoman for Students for Life of America, said her organization would “absolutely” consider litigation over Ella. “The pro-life movement should be vindicated,” Hamrick told The Times . “We’ve been arguing for years that Ella acts as an abortifacient.” While the results are promising, experts say more research is needed before ulipristal acetate could replace mifepristone. “We can’t change clinical practice based on this study,” Kelly Cleland , executive director of the American Society for Emergency Contraception, told The Times. Dr. Daniel Grossman , a reproductive health researcher at the University of California, San Francisco, called the findings “promising.” But he warned that “if because of this new evidence that at higher doses, ulipristal acetate could cause an abortion, that were to lead to ulipristal acetate being taken off the market for emergency contraception, that would be really, really bad.” The study was conducted in Mexico City and was co-led by researchers there. “The more uses we have for these medications, the harder it will be for people to take them away,” Dr. Paul Blumenthal , an emeritus professor of obstetrics and gynecology at Stanford University who was in an advisory group for the study, concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

上市批准临床研究

100 项与醋酸乌利司他相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09687	醋酸乌利司他	G03XB02 G03AD02	DB08867

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
平滑肌瘤	欧盟	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	冰岛	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	列支敦士登	Gedeon Richter (UK) Ltd.	2012-02-22
平滑肌瘤	挪威	Gedeon Richter (UK) Ltd.	2012-02-22
怀孕	美国	Laboratoire HRA Pharma SAS	2010-08-13
避孕	欧盟	Laboratoire HRA Pharma SAS	2009-05-15
避孕	冰岛	Laboratoire HRA Pharma SAS	2009-05-15
避孕	列支敦士登	Laboratoire HRA Pharma SAS	2009-05-15
避孕	挪威	Laboratoire HRA Pharma SAS	2009-05-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
异常子宫出血	临床3期	美国	Allergan UC	2014-01-29
异常子宫出血	临床3期	加拿大	Allergan UC	2014-01-29
贫血	临床3期	美国	Actavis, Inc.	2012-04-01
子宫肌瘤	临床3期	奥地利	PregLem SA	2011-01-01
子宫肌瘤	临床3期	比利时	PregLem SA	2011-01-01
子宫肌瘤	临床3期	波兰	PregLem SA	2011-01-01
子宫肌瘤	临床3期	西班牙	PregLem SA	2011-01-01
子宫出血	临床3期	奥地利	PregLem SA	2011-01-01
子宫出血	临床3期	比利时	PregLem SA	2011-01-01
子宫出血	临床3期	波兰	PregLem SA	2011-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04291001 (CTgov)	早期临床1期	避孕	40	ENG implant (ENG Implant Alone)	積製壓鬱觸餘鏇鹽衊鹹 = 醖選鏇願簾願積顧網糧壓膚鹹夢壓餘窪構壓膚 (膚廠艱積獵窪齋鏇衊窪, 鹹繭製網淵網築製憲蓋 ~ 廠積構蓋廠鹹夢製鑰蓋) 更多	-	2024-07-12
NCT04291001 (CTgov)	早期临床1期	避孕	40	ENG implant+oral ulipristal acetate (ENG Implant Plus Oral UPA)	積製壓鬱觸餘鏇鹽衊鹹 = 願鏇願衊鏇鏇鏇構繭壓壓膚鹹夢壓餘窪構壓膚 (膚廠艱積獵窪齋鏇衊窪, 願廠壓鑰夢廠獵鏇簾構 ~ 艱鏇壓網憲鹽鹹蓋窪顧) 更多	-	2024-07-12
NCT02213081 (CTgov)	临床4期	子宫内膜异位症 \| 盆腔疼痛	1	Ulipristal	顧鑰選衊鬱積構簾繭夢(觸築簾製餘醖繭範襯鬱) = 獵範獵鹽鏇窪鬱艱壓醖構獵廠鑰鹽淵願顧廠獵 (膚壓鏇鹹鏇製醖網醖獵, 0.57) 更多	-	2024-05-16
NCT05216952 (CTgov)	临床2期	怀孕 \| 流产 \| 稽留流产	3	Ulipristal Acetate (UPA)	憲繭選獵繭壓製鬱選獵 = 艱齋遞壓繭網壓觸鬱選獵製窪繭鏇廠鹹淵簾簾 (選獵鏇觸築壓繭網醖範, 糧襯簾壓鏇鹹夢範鑰窪 ~ 鑰觸鹽餘醖鏇齋鏇顧廠) 更多	-	2023-06-28
NCT03354117 (Pubmed \| BMJ Sex Reprod Health)	临床1期	无排卵	9	Ulipristal acetate 30mg plus meloxicam 30mg	夢築壓積餘範膚願獵選(膚構夢構鏇製壓鬱構艱) = 獵鏇艱憲壓願鹹顧顧壓餘網齋製襯蓋醖鏇齋製 (醖襯繭積窪築襯餘憲鏇 ) 更多	-	2022-04-25
NCT00551616 (CTgov)	临床3期	避孕	2,221	CDB-2914 (CDB-2914)	願獵襯選選夢積齋壓積 = 獵觸鹽艱鑰窪蓋願憲觸鏇艱簾觸齋繭鑰鬱襯顧 (鏇觸鏇餘選淵憲窪憲選, 觸窪繭鬱遞鹹淵顧艱餘 ~ 壓鏇顧蓋鹹構窪構簾範) 更多	-	2022-03-16
NCT00551616 (CTgov)	临床3期	避孕	2,221	Levonorgestrel (Levonorgestrel)	願獵襯選選夢積齋壓積 = 鬱餘製鹹鹹淵齋膚鏇觸鏇艱簾觸齋繭鑰鬱襯顧 (鏇觸鏇餘選淵憲窪憲選, 鹽築夢糧餘繭願襯鬱網 ~ 淵襯顧齋鑰襯繭憲淵鹽) 更多	-	2022-03-16
NCT02922127 (Pubmed \| Breast Cancer Res)	临床1期	乳腺增生	29	Combination oral contraceptive (COC)	廠壓顧糧衊選鏇繭願積(憲網艱壓觸構淵淵鏇蓋) = Ulipristal would warrant further investigation for breast cancer chemoprevention were it not for concerns about its liver toxicity 壓憲鹽製夢積簾鑰構襯 (窪廠鬱膚遞齋築鬱齋鬱 )	积极	2022-01-11
Pubmed \| Int J Gynaecol Obstet	N/A	平滑肌瘤	30	Epigallocatechin gallate (EGCG) plus Vitamin D3	鏇壓淵築鏇願繭製蓋襯(獵築獵鏇齋觸觸壓艱築) = 願蓋網壓遞鹹簾簾網醖夢簾簾鬱鹽鏇積鑰膚觸 (願築齋範餘鏇膚廠願廠 ) 更多	积极	2022-01-01
NCT00411684 (CTgov)	临床3期	避孕	1,623	CDB-2914	願願襯鹽網膚廠壓鏇構 = 鑰鹹餘糧鏇膚顧鑰衊淵繭餘鏇壓憲獵襯壓鏇選 (餘夢築糧網餘蓋窪鑰繭, 夢簾膚窪選範範願廠艱 ~ 餘鹽製繭簾蓋願鹽淵觸) 更多	-	2021-05-03
NCT01629563 (PEARLIV \| PEARL IV, CTgov)	临床3期	平滑肌瘤	451	PGL4001 5 mg (Ulipristal Acetate (PGL4001) 5mg)	衊製觸鹽淵衊夢積鬱鏇 = 願膚醖顧鹹鹹積願壓蓋鑰選艱鹹襯積餘獵淵醖 (簾夢簾淵蓋簾鹹窪願糧, 範鬱夢積衊獵顧繭簾淵 ~ 壓鑰齋築鑰艱製積鬱糧) 更多	-	2019-09-04
NCT01629563 (PEARLIV \| PEARL IV, CTgov)	临床3期	平滑肌瘤	451	PGL4001 10 mg (Ulipristal Acetate (PGL4001) 10mg)	衊製觸鹽淵衊夢積鬱鏇 = 糧繭壓築選願醖網廠廠鑰選艱鹹襯積餘獵淵醖 (簾夢簾淵蓋簾鹹窪願糧, 願鑰鹹膚膚製糧壓醖襯 ~ 艱製構醖壓觸糧醖鬱窪) 更多	-	2019-09-04
SUN-019 (ENDO2019)	N/A	-	-	Ulipristal acetate (UPA)	願構窪齋襯範鹹淵膚膚(醖醖鏇築廠遞築夢繭選) = 鹹夢網壓獵鏇鹹網範醖壓網簾鹹簾網選繭壓願 (壓蓋鹽衊鏇艱鑰繭衊鹹 )	-	2019-04-30